path to the prevention of Alzheimer’s disease
unacceptable problem
ounce of prevention
what’s been holding us back
biomarkers may help
25 years before kindred’s median age at clinical onset

mutation carriers, healthy

25 years before kindred’s median age at clinical onset

mutation carriers, healthy

Fleisher et al, Lancet Neurol 2012
relationships between AD measures & age in PSEN1 E280A mutation carriers

Fleisher et al, *JAMA Neurol* (in press)
catch-22
working together
meaningful endpoints
embedding biomarkers
harmonization
sharing trial data & samples
registries
charting new territory
acknowledgements

Partners
Pierre Tariot, Jessica Langbaum & our Genentech & Novartis colleagues
our other colleagues, collaborators, advisors & supporters
our valued research participants

National Institute on Aging
RF1 AG041705, UF1 AG046150, R01 AG031581, P30 AG19610 & FNIH/AMP pending

Industry
Genentech, Novartis & Avid/Eli Lilly

Foundations
Banner Alzheimer’s Foundation, Anonymous Foundation, Nomis Foundation,
Flinn Foundation, Forget Me Not Initiative, Geoffrey Beene Foundation & others pending

Colciencias
1115-408-20512 & 1115-408-20543

State of Arizona
Arizona Alzheimer’s Consortium